GastroPlus User Group

Shanghai, China
May 16-18, 2018

Daejeon, South Korea
May 16-18, 2018

Register for a workshop

With over 900 members and growing…interact with your peers around the globe!*

Visual variability check for population simulations

Do you modify liver blood flow values in GastroPlus PBPK models?

What are your preferred values for the Percent Fluid in SI & Colon in the ACAT model?

Effective GI permeability for pre-clinical species?

*note: must sign into LinkedIn and be a member of the GastroPlus User Group to review and contribute

Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours.

A framework for 2-stage global sensitivity analysis of GastroPlus™ compartmental models.

Monitoring of erlotinib in pancreatic cancer patients during long-time administration and comparison to a physiologically based pharmacokinetic model.

An in vitro – in silico approach for the formulation and characterization of ranitidine gastroretentive delivery systems.

Physiologically-Based Pharmacokinetic Modeling in Lead Optimization I: Evaluation and Adaptation of GastroPlus to Predict Bioavailability of Medchem Series.

Physiologically-Based Pharmacokinetic Modeling in Lead Optimization II: “Rational Bioavailability Design” by Global Sensitivity Analysis to Identify Properties Affecting Bioavailability.